Study of FK778 in Renal Transplant Recipients With Untreated BK Nephropathy

• Status: Terminated
• Trial end date: 2006-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and effectiveness of a new oral immunosuppressant agent compared to standard care in renal transplant patients diagnosed with BK nephropathy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Collaborator: Astellas Pharma US, Inc.

Criteria

Inclusion Criteria:

• Renal transplant recipient with newly diagnosed BK nephropathy.

Exclusion Criteria:

• Previous treatment for BK nephropathy

• Organ transplant other than kidney

• Uncontrolled concomitant infection other than BK nephropathy